Pralatrexate is indicated to treat relapsed or refractory peripheral T-cell lymphoma. Credit: CI Photos / Shutterstock.

US-based biopharmaceutical company CASI Pharmaceuticals has administered the first dose of FOLOTYN (pralatrexate) to a patient with PTCL in China.

Pralatrexate is a dihydrofolate reductase inhibitor indicated to treat relapsed or refractory PTCL.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

When compared with methotrexate, the drug is claimed to internalise effectively into tumour cells, which may translate to an increased anti-cancer effect.

Clinical studies have highlighted pralatrexate’s activity against PTCL, with a registrational study in China reporting an overall response rate (ORR) of 52% and a median progression-free survival (PFS) of 4.8 months.

This compares favourably to the PROPEL study in the US, which showed an ORR of 29% and a median PFS of 3.5 months.

Pralatrexate is currently approved to treat PTCL in the US, Japan and China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month, CASI announced a strategic partnership with the China National Medicines Corporation (CNMC), which marked a key step in marketing FOLOTYN in China.

CNMC has secured sole distribution rights for the product, enhancing CASI’s commercialisation efforts in China.

CASI CEO Dr Wei-Wu He said: “The dosing of the first patient with FOLOTYN in China marks a significant achievement for CASI.

“It reflects our unwavering commitment to bringing advanced therapeutic options to patients, particularly in therapeutic areas with substantial unmet medical needs.

“This is a proud moment for our team and a step forward in our mission to transform patient care through innovation.”

Based in Rockville, Maryland, CASI focuses on developing and marketing new therapeutics and pharmaceutical products for various markets worldwide.

Last November, the company announced that its partner Juventas had received NMPA market approval for CNCT 19, a drug indicated to treat relapsed and refractory B-cell acute lymphoblastic leukaemia, in China.

CNCT 19 is a CD19 CAR-T cell therapy being jointly commercialised and marketed by CASI and Juventas.